ARTEMIS STUDYProspective, Multi-country, Comparative Observational Study (non-interventional) of clinical outcomes that benefit mHSPC patients treated with Apalutamide + ADT and Enzalutamide+ADT under routine clinical practice (ARTEMISpro)
Laufzeit: 01.01.2023 - 31.12.2025
imported
Kurzfassung
Patients with metastatic hormone sensitive prostate cancer (mHSPC).